[1] Vansteenkiste JF,De Leyn PR,Deneffe GJ,et al. Clinical prognostic factors in surgically treated stage ⅢA—N2 non-small cell lung cancer:analysis of the literature[J].Lung Cancer,1998,19(1):3-11.
[2] Betticher DC,Hsu Schmitz SF,Ttsch M,et al. Prognostic factors affecting longterm outcomes in patients with resected stage ⅢA pN2 non-small-cell lung cancer:5-year follow-up of a phase Ⅱ study[J].Br J Cancer,2006,94(8):1099-1106.
[3] Arriagada R,Bergman B,Dunant A,et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer[J].N Engl J Med,2004,350(4):351-310.
[4] Douillard JY,Rosell R,De Lena M,et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage ⅠB–ⅢA nonsmall-cell lung cancer (adjuvant navelbine international trialist association[ANITA]):a randomised controlled trial[J].Lancet Oncol,2006,7(9):719-727.
[5] Winton T,Livingston R,Johnson D,et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer[J].N Engl J Med,2005,352(25):2589-2597.
[6] No authors listed。Postoperative radiotherapy in non-smallcell lung cancer:systematic review and meta-analysis of individual patient data from nine randomised controlled[J].Lancet,1998,352(9124):257-263.
[7] Lally BE,Zelterman D,Colasanto JM,et al. Postoperative radiotherapy for stage Ⅱ or Ⅲ non-small-cell lung cancer using the surveillance,epidemiology,and end results database[J].J Clin Oncol,2006,24(19):2998-3006.
[8] Douillard JY,Rosell R,De Lena M,et al. Impact of postoperative radiation therapy on survival in patients with complete resection and stage Ⅰ,Ⅱ,or ⅢA non-small-cell lung cancer treated with adjuvant chemotherapy:the adjuvant navelbine international trialist association (ANITA) randomized trial[J].Int J Radiat Oncol Biol Phys,2008,72(3):695-701.10.1016/j.ijrobp.2008.01.044.
[9] Ravdin PM1,Davis G.Prognosis of patients with resected non-small cell lung cancer:impact of clinical and pathologic variables[J].Lung Cancer,2006,52(2):207-212.
[10] Sawyer TE,Bonner JA,Gould PM,et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement[J].Cancer,1997,80(8):1399-1408.
[11] Emami B,Kaiser L,Simpson J,et al. Postoperative radiation therapy in non-small cell lung cancer[J].Am J Clin Oncol,1997,20(5):441-448.
[12] The Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage Ⅱ and stage Ⅲ epidermoid cancer of the lung[J].N Engl J Med,1986,315(22):1377-1381.
[13] Feng QF,Wang M,Wang LJ,et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer:a randomized trial[J].Int J Radiat Oncol Biol Phys,2000,47(4):925-929.
[14] Mayer R, Smolle-Juettner FM, Szolar D,et al. Postoperative radiotherapy in radically resected non-small cell lung cancer[J].Chest,1997,112(4):954-959.
[15] Stephens RJ,Girling DJ,Bleehen NM,et al. The role of postoperative radiotherapy in non-small-cell lung cancer:a multicentre randomised trial in patients with pathologically staged T1-2,N1-2,M0 disease[J].Br J Cancer,1996,74(4):632-639.
[16] Choi NC,Grillo HC,Gardiello M,et al. Basis for new strategies in postoperative radiotherapy of bronchogenic carcinoma[J].Int J Radiat Oncol Biol Phys,1980,6(1):31-35.
[17] Scotti V, Meattini I, Saieva C,et al. Post-operative radiotherapy in N2 non-small cell lung cancer:a retrospective analysis of 175 patients[J].Radiother Oncol,2010,96(1):84-88.10.1016/j.radonc.2010.05.010.
[18] Dai H,Hui Z,Ji W,et al. Postoperative radiotherapy for resected pathological stage ⅢA—N2 non-small cell lung cancer:a retrospective study of 221 cases from a single institution[J].Oncologist,2011,16(5):641-650.10.1634/theoncologist.2010-0343.
[19] Billiet C,Decaluwé H,Peeters S,et al. Modern post-operative radiotherapy for stage Ⅲ non-small cell lung cancer may improve local control and survival:a meta-analysis[J].Radiother Oncol,2014,110(1):3-8.10.1016/j.radonc.2013.08.011.
[20] Mantovani C,Levra NG,Filippi AR,et al. Filippi,et al. Postoperative radiotherapy for patients with completely resected pathologic N2 non-small-cell lung cancer:a retrospective analysis[J].Clin Lung Cancer,2013,14(2):194-199.10.1016/j.cllc.2012.05.007.
[21] Matsuguma H,Nakahara R,Ishikawa Y,et al. Postoperative radiotherapy for patients with completely resected pathological stage ⅢA—N2 non-small cell lung cancer:focusing on an effect of the number of mediastinal lymph node stations involved[J].Interact Cardiovasc Thorac Surg,2008,7(4):573-577.10.1510/icvts.2007.174342.
[22] Urban D, Bar J, Solomon B,et al. Solomon,et al. Lymph node ratio may predict the benefit of postoperative radiotherapy in non-small-cell lung cancer[J].J Thorac Oncol,2013,8(7):940-946.10.1097/JTO.0b013e318292c53e.
[23] Jonnalagadda S,Arcinega J,Smith C,et al. Validation of the lymph node ratio as a prognostic factor in patients with N1 nonsmall cell lung cancer[J].Cancer,2011,117(20):4724-4731.10.1002/cncr.26093.
[24] Matsuguma H,Oki I,Nakahara R,et al. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes[J].Eur J Cardiothorac Surg,2012,41(1):19-24.10.1016/j.ejcts.2011.04.016.
[25] Nwogu CE,Groman A,Fahey D,et al. Number of lymph nodes and metastatic lymph node ratio are associated with survival in lung cancer[J].Ann Thorac Surg,2012,93(5):1614-1619;discussion 1619-1620.10.1016/j.athoracsur.2012.01.065.
[26] Wang CL,Li Y,Yue DS,et al. Value of the metastatic lymph node ratio for predicting the prognosis of non-small-cell lung cancer patients[J].World J Surg,2012,36(2):455-462.10.1007/s00268-011-1360-8.
[27] Moretti L, Yu DS, Chen H,et al. Prognostic factors for resected non-small cell lung cancer with pN2 status:implications for use of postoperative radiotherapy[J].Oncologist,2009,14(11):1106-1110.10.1634/theoncologist.2009-0130. |